How Digital Pathology Is Turbocharging Neuroscience Drug Discovery

KNOXVILLE, Tenn. and PHILADELPHIA – February 17, 2026 – In the high-stakes race to develop treatments for neurological diseases, speed and precision are paramount. A strategic partnership is demonstrating how digital innovation can dramatically accelerate this process, with specialized contract research organization (CRO) NeuroScience Associates (NSA Labs) reporting significant efficiency gains across 750 studies by leveraging Proscia’s Concentriq® software platform. The collaboration highlights a critical inflection point in preclinical research, where digital pathology is moving from a novel technology to an essential tool for accelerating breakthroughs.

Since adopting the platform in 2018, NSA Labs has streamlined its complex neurohistology workflows, enhancing everything from digital imaging and analysis to sponsor collaboration. This integration is proving vital in a field where research timelines can stretch for years and the cost of failure is immense. For the leading biopharmaceutical companies that partner with NSA Labs, this means getting crucial study results faster, enabling quicker, more confident decisions about which drug candidates to advance.

The Digital Shift in Neurohistology

At the heart of this acceleration is the powerful combination of specialized physical processing and a sophisticated digital backbone. NSA Labs has long been a leader in high-throughput neurohistology, thanks to its proprietary MultiBrain® and MultiCord® technologies. These methods allow for the simultaneous processing of dozens of brain or spinal cord samples in a single block, ensuring uniformity and slashing histology timelines by a factor of up to 40 compared to traditional methods.

While this physical innovation provides the foundation for speed, Proscia's Concentriq platform acts as the digital accelerator. It centralizes the vast amounts of image data generated from slide scanning, creating a unified workspace for scientists and sponsors. This digital environment eliminates the logistical bottlenecks associated with shipping physical glass slides and enables seamless, real-time collaboration.

“In complex drug development, speed depends on shared visibility and a clear path from results to decisions,” said Tate York, Director of Imaging and Analysis at NeuroScience Associates. “Concentriq brings our scientists and sponsor teams into one workspace, so sponsors can quickly interpret findings, make decisions, and advance their programs with clarity and confidence.”

The platform's widespread adoption—used by 16 of the top 20 pharmaceutical companies—creates a powerful network effect. When NSA Labs delivers study results on Concentriq, sponsor companies can directly integrate that data into their existing downstream R&D workflows without friction, preserving data integrity and saving valuable time.

Breaking Down Barriers in Drug Discovery

This acceleration comes at a critical time. Drug development for central nervous system (CNS) disorders is notoriously complex, lengthy, and expensive. Researchers face immense challenges, including the intricate biology of the brain, the difficulty of delivering drugs across the blood-brain barrier, and a historical lack of predictive animal models. These hurdles contribute to high failure rates in clinical trials and concentrate investment on a narrow range of blockbuster indications, leaving many neurological conditions underserved.

Digital pathology is emerging as a key technology to help mitigate these challenges. Industry-wide, the transition from glass slides to digital images has been shown to boost pathologist efficiency by 15-20% per case. When integrated with artificial intelligence, some platforms have demonstrated productivity gains of up to 37%. By streamlining workflows and enabling high-throughput analysis, these systems allow researchers to screen more compounds and analyze more tissue samples in less time.

For neuroscience, the benefits are particularly pronounced. The ability for multiple experts across different continents to view and annotate the same digital slide simultaneously fosters a level of collaboration that was previously impossible. This is crucial for interpreting the subtle and complex changes in neural tissue that can signify a drug’s efficacy or toxicity. Furthermore, a centralized digital archive provides an invaluable resource for long-term studies and allows for the application of new AI-driven image analysis algorithms to historical data, potentially unlocking new insights from past research.

A New Era of CRO-Pharma Collaboration

The NSA Labs and Proscia partnership also signifies a broader shift in the biopharmaceutical landscape, where CROs are evolving from simple service providers into integral technology and innovation partners. By adopting cutting-edge platforms like Concentriq, specialized CROs can offer enhanced value, embedding themselves more deeply into their clients' R&D ecosystems.

NSA Labs leverages the platform not only for internal analysis but also as a direct-to-sponsor data delivery service. Clients are given direct access to their histology images on the platform, allowing their internal teams to view, analyze, and share findings alongside the formal study results. This transparency transforms the traditional, often siloed, relationship into a dynamic, collaborative partnership, reducing the risk of miscommunication and accelerating the decision-making cycle.

“NSA Labs continues to raise the bar for speed, quality, and collaboration in neurohistology,” commented David West, CEO of Proscia. “This standard of excellence is why many of the world’s largest pharmaceutical companies rely on its team for complex drug development programs.”

The Competitive Edge in a Growing Market

Proscia’s success with major pharmaceutical clients and leading CROs places it in a strong position within the rapidly growing and competitive digital pathology market. The company’s recognition as the Global 2026 Best in KLAS for Digital Pathology in Europe, an award based entirely on customer feedback, underscores the reliability and performance of its platform. According to KLAS Research, 100% of surveyed customers would buy Concentriq again, citing its trustworthiness for primary diagnosis and Proscia’s dependable support.

This market includes other major players like Philips, with its end-to-end IntelliSite solution, and AI-focused companies such as Paige and PathAI, which are pioneering AI-driven diagnostics in oncology. Other firms like Indica Labs are also gaining ground with FDA-cleared solutions for diagnosis and research. This competitive pressure is fueling a wave of innovation across the industry, with an increasing focus on cloud-native platforms, interoperability, and the integration of powerful AI tools to further enhance diagnostic accuracy and research efficiency.

By integrating specialized physical techniques with a powerful digital backbone, the industry is building a more efficient and collaborative R&D ecosystem. This synergistic model, exemplified by the work of NSA Labs and Proscia, holds the promise of shortening the arduous path from the laboratory bench to life-changing patient therapies for a host of devastating neurological disorders.